百奥赛图携手Envigo共同推进重度免疫缺陷B-NDG小鼠销售
中国北京，2021年9月28日 – 百奥赛图宣布与Envigo达成动物模型的销售合作。Envigo是一家提供涵盖范围广泛的研究模型及相关服务的跨国企业。双方将共同致力于推进重度免疫缺陷B-NDG小鼠模型在相关研究领域的广泛应用。Envigo作为区域独家供应商负责百奥赛图B-NDG小鼠在美国、欧洲和部分亚太地区的销售。
B-NDG小鼠是百奥赛图自主研发，通过在NOD-scid背景上敲除IL2rg基因构建而成的重度免疫缺陷小鼠。该小鼠缺乏成熟的T、B和功能性的NK细胞，并表现出细胞因子信号转导功能缺失，其重度免疫缺陷表型使得该小鼠能够被用来进行包括人免疫细胞在内的异种细胞移植实验。该模型广泛应用于肿瘤学、肿瘤免疫学、传染病和干细胞生物学等领域的研究和药物发现。
Envigo总裁兼首席执行官Adrian Hardy博士表示：“我们与百奥赛图的合作进一步扩大了Envigo客户可选择的模型种类。B-NDG小鼠模型与在此基础上构建的二代模型为重要治疗方法的研究及开发提供了现有免疫缺陷模型的强大替代产品。”
百奥赛图董事长兼首席执行官沈月雷博士表示：“两家公司都致力于为基础研究和药物开发提供优秀的临床前模型。 我们相信，基于百奥赛图构建的高质量小鼠模型以及Envigo世界先进的繁育设施和小鼠健康监测体系的合作可以更好地满足相关领域的需求。”
关于百奥赛图
百奥赛图是一家创新技术驱动新药研发的国际性生物技术公司，致力于成为全球新药发源地，以专注技术创新、持续新药产出、守护人类健康为使命。基于免疫功能健全，能产生高度多样化、卓越亲和力全人抗体的RenMab® 和 RenLite® 小鼠，百奥赛图将单细胞抗体发现技术平台、基因编辑模型开发平台、大规模动物生产平台及药物筛选平台有机整合在一起，形成了独具特色、涵盖药物研发全流程的新药研发体系。百奥赛图积极推动新药自主研发及与外部的合作开发。
详情请访问：www.biocytogen.com.cn
关于 Envigo
Envigo (Envigo RMS LLC) 为制药和生物技术行业、政府、学术界和其他生命科学组织提供广泛的研究模型和相关服务。作为专注提供研究模型和相关产品及服务的最大规模机构，我们致力于帮助研究者充分挖掘其重要研发项目的潜力，与合作方一起共同努力完成建设一个更健康、更安全的世界的使命。
详情请访问： www.envigo.com
Beijing, China, [September 28th], 2021 – Biocytogen announces a collaboration with Envigo, a global organization offering the broadest range of research models and related services. The two companies are committed to supporting research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the United States, Europe, and certain Asia-Pacific regions.
The triple immunodeficient B-NDG mouse model was independently designed and produced by Biocytogen. B-NDG mice were created by deleting the IL2rg gene from NOD-scid mice with severe immunodeficiency phenotype. Lacking mature T cells, B cells or functional NK cells, and displaying cytokine signaling deficiencies, this mouse model is highly immunodeficient and capable of supporting human immune cell transplantation. The model is widely used in research and drug discovery in many fields including oncology, immuno-oncology, infectious disease, and stem cell biology.
Dr Adrian Hardy, President and CEO of Envigo, commented: “Our collaboration with Biocytogen further expands the range of models available to Envigo’s customers. The B-NDG model and future models to follow, offer a robust alternative to existing immunodeficient models for critical research and the development of life-saving therapies.”
Dr Yuelei Shen, President and CEO of Biocytogen, said: “Both companies are dedicated to supply good non-clinical models for basic research and drug development. We believe that such collaboration leveraging the high quality of mouse models generated by Biocytogen and the state-of-the-art breeding facilities & health monitoring programs at Envigo can satisfy the needs in those related fields.”
About Biocytogen
Biocytogen is a global biotech company that drives the research and development of new drugs with innovative technologies. The company is committed to becoming a global headstream of new drugs and bringing the benefits to patients around the world as its mission. Based on the fully human antibody RenMab™ and RenLite™ mice for fully human antibodies production with robust humoral responses, highly diverse antibody repertoire and superior affinity, Biocytogen has integrated its platforms in single-cell antibody discovery, gene editing, large-scale animal model supply, and screening to form a new approach to streamline the entire drug development process. Biocytogen actively promotes the independent and cooperative development of new drugs. For more, please visit www.biocytogen.com
About Envigo
Envigo (Envigo RMS LLC) provides the broadest range of research models and related services to the pharmaceutical and biotechnology industries, government, academia and other life science organizations. As the largest organization that is solely dedicated to providing research models and related products and services, we are committed to helping researchers realize the full potential of their critical R&D projects as we fulfill our mission to work together to build a healthier and safer world. For more, please visit www.envigo.com
推荐阅读